Cancer immunotherapy has many faces

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. - PubMed - NCBI
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. – PubMed – NCBI

 

Cancer immunotherapy has many faces. One of them are checkpoint inhibitors, such as pembrolizumab, which is a humanized monoclonal antibody against programmed death 1 (PD-1).

The New England Journal of Medicine just published results from a phase 3 cinical trial, showing that immunotherapy with the PD-1 inhibitor pembrolizumab is more effective in the treatment of PD-L1 positive advanced non-small-cell lung cancer (NSCLC) than chemotherapy.

These results do not only show the potential of cancer immunotherapy but also highlights the importance of getting your cancer tissue tested for genetic characteristics and surface markers to find the best treatment option for you.

 

https://www.ncbi.nlm.nih.gov/pubmed/27718847